Literature DB >> 1288512

Comparison of the efficacy and tolerance of a garlic preparation vs. bezafibrate.

H Holzgartner1, U Schmidt, U Kuhn.   

Abstract

The efficacy and tolerance of a garlic preparation (Sapec, Kwai) was investigated in a randomized double-blind study vs. bezafibrate. This multi-centre study was conducted in 5 general medical practices and involved 98 patients with primary hyperlipoproteinaemia. The daily doses of the active substances were 900 mg of garlic powder (standardized as to 1.3% alliin) and 600 mg of bezafibrate, respectively. The pre-phase with placebo lasted 6 weeks, the treatment period covered 12 weeks. All patients were advised to observe a low-fat "step-1 diet" for the duration of the study. The 98 case report forms allowed the statistical evaluation of total cholesterol, HDL cholesterol and triglyceride levels for 94 patients, and of LDL cholesterol values for 92 patients. In the course of the treatment both study medications caused a statistically highly significant reduction in total cholesterol, in LDL cholesterol and triglycerides, and an increase in HDL cholesterol. However, there was no significant difference in the efficacies of both medication groups. Side effects were mentioned by 5 patients each in both treatment groups, none of which led to the withdrawal of the patients. Concerning the garlic preparation, there was no correlation between the perception of garlic odour and the influence on the cholesterol level.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1288512

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  11 in total

Review 1.  Garlic for the prevention of cardiovascular morbidity and mortality in hypertensive patients.

Authors:  Sarah N Stabler; Aaron M Tejani; Fong Huynh; Claire Fowkes
Journal:  Cochrane Database Syst Rev       Date:  2012-08-15

2.  Differential inhibitory effects of garlic-derived organosulfur compounds on cholesterol biosynthesis in primary rat hepatocyte cultures.

Authors:  R Gebhardt; H Beck
Journal:  Lipids       Date:  1996-12       Impact factor: 1.880

Review 3.  Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia.

Authors:  K L Goa; L B Barradell; G L Plosker
Journal:  Drugs       Date:  1996-11       Impact factor: 9.546

4.  A review of studies of garlic (Allium sativum) on serum lipids and blood pressure before and after 1994: does the amount of allicin released from garlic powder tablets play a role?

Authors:  Marc P McRae
Journal:  J Chiropr Med       Date:  2005

5.  Effect of garlic on blood pressure: a meta-analysis.

Authors:  Hai-Peng Wang; Jing Yang; Li-Qiang Qin; Xiang-Jun Yang
Journal:  J Clin Hypertens (Greenwich)       Date:  2015-01-05       Impact factor: 3.738

Review 6.  Use of lipid-lowering medicinal herbs during pregnancy: A systematic review on safety and dosage.

Authors:  Hojjat Rouhi-Boroujeni; Esfandiar Heidarian; Hamid Rouhi-Boroujeni; Minasadat Khoddami; Mojgan Gharipour; Mahmoud Rafieian-Kopaei
Journal:  ARYA Atheroscler       Date:  2017-05

7.  Garlic lowers blood pressure in hypertensive subjects, improves arterial stiffness and gut microbiota: A review and meta-analysis.

Authors:  Karin Ried
Journal:  Exp Ther Med       Date:  2019-12-27       Impact factor: 2.447

8.  Role of garlic usage in cardiovascular disease prevention: an evidence-based approach.

Authors:  Waris Qidwai; Tabinda Ashfaq
Journal:  Evid Based Complement Alternat Med       Date:  2013-04-17       Impact factor: 2.629

Review 9.  Effect of garlic on blood pressure: a systematic review and meta-analysis.

Authors:  Karin Ried; Oliver R Frank; Nigel P Stocks; Peter Fakler; Thomas Sullivan
Journal:  BMC Cardiovasc Disord       Date:  2008-06-16       Impact factor: 2.298

10.  Garlic powder intake and cardiovascular risk factors: a meta-analysis of randomized controlled clinical trials.

Authors:  Jin Sook Kwak; Ji Yeon Kim; Ju Eun Paek; You Jin Lee; Haeng-Ran Kim; Dong-Sik Park; Oran Kwon
Journal:  Nutr Res Pract       Date:  2014-11-28       Impact factor: 1.926

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.